BACK
IMAC Holdings, Inc.
Medical - Care Facilities
Market Cap$77K
5Y Perf.-99.9%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
BACK vs ATXI
Revenue, margins, valuation, and 5-year total return — side by side.
ATXI
Avenue Therapeutics, Inc.
Biotechnology
Market Cap$2M
5Y Perf.-100.0%
BACK vs ATXI — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | BACK | ATXI |
|---|---|---|
| Industry | Medical - Care Facilities | Biotechnology |
| Market Cap | $77K | $2M |
| Revenue (TTM) | $23K | $1M |
| Net Income (TTM) | $-10M | $-4M |
| Gross Margin | -18.4% | 100.0% |
| Operating Margin | -398.1% | -279.8% |
| Total Debt | $0.00 | $0.00 |
| Cash & Equiv. | $504K | $3M |
BACK vs ATXI — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
BACK
ATXI
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| IMAC Holdings, Inc. (BACK) | 100 | 0.1 | -99.9% |
| Avenue Therapeutics… (ATXI) | 100 | 0.0 | -100.0% |
Price return only. Dividends and distributions are not included.
Quick Verdict: BACK vs ATXI
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: ATXI leads in 4 of 5 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. IMAC Holdings, Inc. is the stronger pick specifically for dividend income and shareholder returns. As sector peers, any of these can serve as alternatives in the same allocation.
BACK
IMAC Holdings, Inc.
The Long-Run Compounder
BACK is the clearest fit if your priority is long-term compounding.
- -100.0% 10Y total return vs ATXI's -100.0%
- 100.0% yield; 1-year raise streak; the other pay no meaningful dividend
Best for: long-term compounding
ATXI
Avenue Therapeutics, Inc.
The Growth Play
ATXI carries the broadest edge in this set and is the clearest fit for growth exposure and sleep-well-at-night.
- EPS growth 98.8%
- Lower volatility, beta -0.11, current ratio 3.27x
- Beta -0.11, current ratio 3.27x
Best for: growth exposure and sleep-well-at-night
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | ATXI | -30.5% revenue growth vs BACK's -98.6% |
| Quality / Margins | ATXI | -266.7% margin vs BACK's -426.9% |
| Dividends | BACK | 100.0% yield; 1-year raise streak; the other pay no meaningful dividend |
| Momentum (1Y) | ATXI | +111.6% vs BACK's -15.6% |
| Efficiency (ROA) | ATXI | -105.8% ROA vs BACK's -31.3% |
BACK vs ATXI — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLATXILAGGINGBACK
BACKIMAC Holdings, Inc.
1leads
ATXIAvenue Therapeutics, …
4leads
6 Total Categories
CATEGORYLEADERvs BACKMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
ATXI5/5
Valuation MetricsMultiples, price ratios, and targets
ATXI1/1
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
ATXI3/3
Total Returns1Y, 3Y, 5Y total returns with dividends
BACK4/6
Risk & VolatilityBeta, volatility, and downside exposure
ATXI2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
ATXI leads this category, winning 5 of 5 comparable metrics.
Income & Cash Flow (Last 12 Months)
ATXI is the larger business by revenue, generating $1M annually — 61.8x BACK's $22,723. ATXI is the more profitable business, keeping -2.7% of every revenue dollar as net income compared to BACK's -426.9%.
| Metric | BACKIMAC Holdings, In… | ATXIAvenue Therapeuti… |
|---|---|---|
| RevenueTrailing 12 months | $22,723 | $1M |
| EBITDAEarnings before interest/tax | -$9M | -$4M |
| Net IncomeAfter-tax profit | -$10M | -$4M |
| Free Cash FlowCash after capex | -$5M | -$2M |
| Gross MarginGross profit ÷ Revenue | -18.4% | +100.0% |
| Operating MarginEBIT ÷ Revenue | -398.1% | -2.8% |
| Net MarginNet income ÷ Revenue | -426.9% | -2.7% |
| FCF MarginFCF ÷ Revenue | -215.1% | -124.1% |
| Rev. Growth (YoY)Latest quarter vs prior year | -62.3% | — |
| EPS Growth (YoY)Latest quarter vs prior year | +26.3% | +89.1% |
ATXI leads this category, winning 5 of 5 comparable metrics.
Valuation Metrics
ATXI leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
| Metric | BACKIMAC Holdings, In… | ATXIAvenue Therapeuti… |
|---|---|---|
| Market CapShares × price | $77,135 | $2M |
| Enterprise ValueMkt cap + debt − cash | -$427,054 | -$842,479 |
| Trailing P/EPrice ÷ TTM EPS | -0.00x | -0.61x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 1.07x | — |
| Price / BookPrice ÷ Book value/share | — | 3.84x |
| Price / FCFMarket cap ÷ FCF | — | — |
ATXI leads this category, winning 1 of 1 comparable metric.
Profitability & Efficiency
ATXI leads this category, winning 3 of 3 comparable metrics.
Profitability & Efficiency
On the Piotroski fundamental quality scale (0–9), ATXI scores 2/9 vs BACK's 1/9, reflecting mixed financial health.
| Metric | BACKIMAC Holdings, In… | ATXIAvenue Therapeuti… |
|---|---|---|
| ROE (TTM)Return on equity | — | -160.6% |
| ROA (TTM)Return on assets | -31.3% | -105.8% |
| ROICReturn on invested capital | — | — |
| ROCEReturn on capital employed | — | -9.0% |
| Piotroski ScoreFundamental quality 0–9 | 1 | 2 |
| Debt / EquityFinancial leverage | — | — |
| Net DebtTotal debt minus cash | -$504,189 | -$3M |
| Cash & Equiv.Liquid assets | $504,189 | $3M |
| Total DebtShort + long-term debt | $0 | $0 |
| Interest CoverageEBIT ÷ Interest expense | -28.20x | — |
ATXI leads this category, winning 3 of 3 comparable metrics.
Total Returns (Dividends Reinvested)
BACK leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in BACK five years ago would be worth $7 today (with dividends reinvested), compared to $1 for ATXI. Over the past 12 months, ATXI leads with a +111.6% total return vs BACK's -15.6%. The 3-year compound annual growth rate (CAGR) favors BACK at -80.3% vs ATXI's -80.7% — a key indicator of consistent wealth creation.
| Metric | BACKIMAC Holdings, In… | ATXIAvenue Therapeuti… |
|---|---|---|
| YTD ReturnYear-to-date | -69.8% | -19.8% |
| 1-Year ReturnPast 12 months | -15.6% | +111.6% |
| 3-Year ReturnCumulative with dividends | -99.2% | -99.3% |
| 5-Year ReturnCumulative with dividends | -99.9% | -100.0% |
| 10-Year ReturnCumulative with dividends | -100.0% | -100.0% |
| CAGR (3Y)Annualised 3-year return | -80.3% | -80.7% |
BACK leads this category, winning 4 of 6 comparable metrics.
Risk & Volatility
ATXI leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
ATXI is the less volatile stock with a -0.11 beta — it tends to amplify market swings less than BACK's 0.05 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. ATXI currently trades 56.7% from its 52-week high vs BACK's 18.1% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | BACKIMAC Holdings, In… | ATXIAvenue Therapeuti… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.05x | -0.11x |
| 52-Week HighHighest price in past year | $0.21 | $0.97 |
| 52-Week LowLowest price in past year | $0.03 | $0.15 |
| % of 52W HighCurrent price vs 52-week peak | +18.1% | +56.7% |
| RSI (14)Momentum oscillator 0–100 | 40.8 | 53.6 |
| Avg Volume (50D)Average daily shares traded | 3K | 3K |
ATXI leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
BACK is the only dividend payer here at 100.00% yield — a key consideration for income-focused portfolios.
| Metric | BACKIMAC Holdings, In… | ATXIAvenue Therapeuti… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | — |
| Price TargetConsensus 12-month target | — | — |
| # AnalystsCovering analysts | — | — |
| Dividend YieldAnnual dividend ÷ price | +100.0% | — |
| Dividend StreakConsecutive years of raises | 1 | — |
| Dividend / ShareAnnual DPS | $0.80 | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
ATXI leads in 4 of 6 categories (Income & Cash Flow, Valuation Metrics). BACK leads in 1 (Total Returns).
Best OverallAvenue Therapeutics, Inc. (ATXI)Leads 4 of 6 categories
Loading custom metrics...
BACK vs ATXI: Frequently Asked Questions
7 questions · data-driven answers · updated daily
01Which is the better long-term investment — BACK or ATXI?
Over the past 5 years, IMAC Holdings, Inc.
(BACK) delivered a total return of -99. 9%, compared to -100. 0% for Avenue Therapeutics, Inc. (ATXI). Over 10 years, the gap is even starker: BACK returned -100. 0% versus ATXI's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
02Which is safer — BACK or ATXI?
By beta (market sensitivity over 5 years), Avenue Therapeutics, Inc.
(ATXI) is the lower-risk stock at -0. 11β versus IMAC Holdings, Inc. 's 0. 05β — meaning BACK is approximately -142% more volatile than ATXI relative to the S&P 500.
03Which is growing faster — BACK or ATXI?
On earnings-per-share growth, the picture is similar: Avenue Therapeutics, Inc.
grew EPS 98. 8% year-over-year, compared to -5. 4% for IMAC Holdings, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
04Which has better profit margins — BACK or ATXI?
Avenue Therapeutics, Inc.
(ATXI) is the more profitable company, earning -266. 7% net margin versus -125. 5% for IMAC Holdings, Inc. — meaning it keeps -266. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ATXI leads at -279. 8% versus -78. 0% for BACK. At the gross margin level — before operating expenses — ATXI leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
05Which pays a better dividend — BACK or ATXI?
In this comparison, BACK (100.
0% yield) pays a dividend. ATXI does not pay a meaningful dividend and should not be held primarily for income.
06Is BACK or ATXI better for a retirement portfolio?
For long-horizon retirement investors, IMAC Holdings, Inc.
(BACK) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 05), 100. 0% yield). Both have compounded well over 10 years (BACK: -100. 0%, ATXI: -100. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
07What are the main differences between BACK and ATXI?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: BACK is a small-cap income-oriented stock; ATXI is a small-cap quality compounder stock. BACK pays a dividend while ATXI does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.